Cargando…
Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor pathways for the treatment for EGFR‐mutated, metastatic non‐small cell lung cancer is supported by previous randomized controlled trials. However, the use of second‐generation irreversible EGFR tyro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058312/ https://www.ncbi.nlm.nih.gov/pubmed/35343086 http://dx.doi.org/10.1111/1759-7714.14396 |